A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Pazopanib (Primary) ; Diphenhydramine; Temsirolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 11 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2016 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.